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Abstract 
Background: Various thiourea derivatives have been used as starting materials for compounds with better biological 
activities. Molecular modeling tools are used to explore their mechanism of action.
Results: A new series of thioureas were synthesized. Fluorinated pyridine derivative 4a showed the highest anti‑
microbial activity (with MIC values ranged from 1.95 to 15.63 µg/mL). Interestingly, thiadiazole derivative 4c and 
coumarin derivative 4d exhibited selective antibacterial activities against Gram positive bacteria. Fluorinated pyridine 
derivative 4a was the most active against HepG2 with IC50 value of 4.8 μg/mL. Molecular docking was performed on 
the active site of MK‑2 with good results.
Conclusion: Novel compounds were obtained with good anticancer and antibacterial activity especially fluorinated 
pyridine derivative 4a and molecular docking study suggest good activity as mitogen activated protein kinase‑2 
inhibitor.
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Background
Fluorinated compounds are intriguing for the develop-
ment of pharmaceuticals, agrochemicals, and materials, 
and thus, much effort has been exerted to develop more 
general and efficient approaches for introducing fluorine 
atom(s) or fluoroalkyl group(s) into organic molecules 
[1–4]. The unique properties of fluoro organic molecules 
may arise from the properties such as (i) the greatest elec-
tronegativity of fluorine, (ii) the largest strength of the 
carbon–fluorine bond, (iii) the hardness and the low van 
der Waals interaction due to the low polarizability, (iv) 
the increased hydrophobicity, and (v) the second small-
est atomic radius of the fluorine atom. These factors are 
operative singly or sometimes cooperatively to affect the 
pharmacological properties of the fluorinated molecules 
[5]. The majority of fluorinated drugs are constructed by 
five- and six-membered nitrogen heterocycles containing 
fluorine, trifluoromethyl, difluoromethyl, fluoromethyl, 
2,2,2-trifluoroethyl, and pentafluoroethyl groups [6]. An 
increasing number of fluorinated antimitotic/antitumour 
agents have now becoming available for cancer treat-
ment. The most widely used are the 5-fluoropyrimidines 
such as 5-fluorouracil (5-FU) and 5-fluoro-2\-deoxy-
uridine (FdUrd) [7, 8], (Fig.  1). The thiourea derivatives 
represent one of the most promising classes of anticancer 
agents with a wide range of activities against various leu-
kemia and solid tumors [9–17]. They play an important 
role as anticancer agents because of their good inhibitory 
activity against protein tyrosine kinases (PTKs), [10–13] 
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human sirtuin type proteins 1 and 2 (SIRT1 and SIRT2), 
[14] topoisomerase II [15] and DNA repair synthesis 
[16]. Furthermore, fluorinated aryl thioureas represent 
a new class of potent anti-trypanosomal agents [18] and 
also a novel class of potent influenza virus neuramini-
dase inhibitors [19]. Thiocarlide is a pharmacologically 
important thiourea drug that is used as a therapeutic 
agent in the treatment of tuberculosis [20] and Pheneth-
ylthiazoylthiourea (PETT) derivatives (LY73497 and 
trovirdine HCl) [21, 22] have been discovered as potent 
inhibitors of HIV type 1, (Fig. 1).
Literature survey revealed that sulfonamides are a sig-
nificant class of compounds in medicinal and pharma-
ceutical chemistry with several biological applications 
[23]. Today, they are widely used as antimicrobial agent, 
chiefly because of their low cost, low toxicity and excel-
lent activity against bacterial diseases [24]. Some impor-
tant sulfonamide derivatives used as carbonic anhydrase 
inhibitors of commercial importance [25]. They are also 
effective for the treatment of urinary, intestine, and oph-
thalmic infections, scalds, ulcerative colitis [26], rheu-
matoid arthritis [27], male erectile dysfunction as the 
phosphodiesterase-5 inhibitor sildenafil-better known 
under its commercial name, Viagra [28], and obesity 
[29]. More recently, sulfonamides are used as an anti-
cancer agent [30], as the antiviral HIV protease inhibi-
tor amprenavir [31] and in Alzheimer’s disease [32]. 
Prompted by the above facts and in continuation of our 
interest in biologically active compounds [33–35] we 
hereby report the synthesis of some novel of fluorinated 
N-(2,6-dimethoxypyrimidin-4-yl)-4-(3-(aryl)thioureido)
benzenesulfonamides 3a–e and 4a–d from readily avail-




Isothiocyanates are useful and widely used building 
blocks in the synthesis of nitrogen, sulfur and oxygen 
heterocycles and organometallic compounds of aca-
demic, pharmaceutical and industrial interest [36]. The 
high electrophilicity and nucleophilicity associated with 
the carbon and sulfur atoms, respectively, of the isothi-
ocyanates and their extended π electron system make 
them unique precursors of a large variety of target mol-
ecules. Consequently, many classes of five and six-mem-
bered nitrogen and sulfur heterocycles, either carrying 
various substituents or fused with benzo or non-benzo 
nuclei to interesting poly heterocycles, have been syn-
thesized from isothiocyanates which is undoubtedly a 
landmark in organosulfur chemistry [37]. The interme-
diate, N-(2,6-dimethoxypyrimidin-4-yl)-4-isothiocy-
anatobenzenesulfonamide 2 used for the preparation of 
target compounds have been synthesized in high yield 
via thiophosgenation of sulfa-dimethoxazine 1 at room 
temperature in the presence of dilute hydrochloric acid, 
according to literature procedure [38] (Scheme 1).
The synthesis of N-(2,6-dimethoxypyrimidin-4-yl)-
4-(3-(aryl) thio-ureido)benzenesulfonamides 3a–e is 
outlined in Scheme 2. Treatment of isothiocyanato ben-
zenesulfonamide 2 with a variety of fluorinated aro-
matic amines in dry dioxane at reflux temperature in 
Fig. 1 Fluorinated and thiourea anticancer agents
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the presence of a catalytic amounts of triethylamine 
furnished the novel fluorinated N,N-disubstituted thio-
ureas 3a–e in high yields (80–92%).The structure of the 
products 3a–e were established via inspection of their 
spectral data. Thioureas 3a–e were confirmed by the 
absence of characteristic infrared absorption peak at 
2000–2200 cm−1 (N=C=S group). Also, the infrared of 3 
is characterized by the presence of the NH, CN, thiocar-
bonyl (CS) and  SO2 absorption bands. For example, the 
1H NMR of compound 3a showed two singlets at δ 3.81, 
3.84  ppm which were assigned for two methoxy pro-
tons, a singlet at δ 5.9 ppm assigned to the pyrimidine-
H, two downfield singlets at δ 11.8, and 14.0 ppm which 
were readily assigned to the HN(1) and HN(2) protons, 
in addition to the presence of  SO2NH and aromatic pro-
tons. The thiocarbonyl group of thiourea moiety was also 
observed in 13C-NMR. The formation of thiourea 3a–e 
can be explained by the reaction pathway depicted in 
Fig. 2.
The nucleophilic attack of the amino group of the aro-
matic amine on thiocarbonyl group of isothiocyanate 
leads to formation of an intermediate (A). During the 
consecutive steps, deprotonation and protonation of the 
intermediate results in the formation of the final product 
thiourea. Under similar reaction conditions, treatment 
of isothiocyanate 2 with fluorinated heterocyclic amines 
such as 2-amino-2,3,5,6-tetrafluoropyridine, 2-amino-
6-fluorobenzothiazole, 2-amino-5-(trifluoromethyl)-1,3,4-
thiadiazole and 7-amino-4-(trifluoromethyl)-coumarine 
afforded the corresponding fluorinated heterocyclic thio-
ureas 4a–d, (Scheme 3). The composition and structure of 
products 4a–d were confirmed by the results of elemental 
analysis and data of IR and NMR spectra. The infrared of 
structure 4 displayed absorption band assignable for NH, 
thiocarbonyl (CS) and  SO2 groups. The infrared of 4c 
exhibited stretching frequencies at 3415, 3310, 2978, 2841 
and 1618 cm−1 for the two NH, CH-aliph and CN groups, 
in addition to the presence of absorption bands corre-
sponding to  SO2 and CS at 1311, 1195, 1274 cm−1. Its 1H 
NMR showed two singlets at δ 3.64, 3.66 ppm which were 
assigned for two methoxy protons, a singlet at δ 6.5 ppm 
assigned to the pyrimidine-H, two downfield singlets at 
δ 11.8, and 12.4 ppm which were readily assigned to the 
HN(1) and HN(2) protons, in addition to the presence of 
 SO2NH and aromatic protons (Scheme 3).
Antimicrobial evaluation
The newly synthesized target compounds were evalu-
ated for their in vitro antibacterial activity against Strep-
tococcus pneumoniae and Bacillus subtilis as examples 
of Gram-positive bacteria and Pseudomonas aeruginosa 
and Escherichia coli as examples of Gram-negative bacte-
ria. They were also evaluated for their in vitro antifungal 
potential against a representative panel of fungal strains 
i.e. Aspergillus fumigatus, and Candida albicans. The 
organisms were tested against the activity of solutions 
of concentrations (1  mg/mL) and using inhibition zone 
diameter in mm as criterion for the antimicrobial activ-
ity (agar well diffusion method). The results of testing for 
antibacterial and antifungal effects are summarized in 
Table 1. As shown by these results, the newly synthesized 
compounds tested displayed variable in  vitro antibacte-
rial and antifungal activities.
From the screening results, it can be seen that com-
pound 4a showed the highest activity against Gram 
positive bacteria B. subtilis followed by compounds 
4c, 4d, 3d and 4b, respectively. Similarly, compound 
4a showed the highest activity against Gram positive 
bacteria S. pneumoniae followed by compounds 4d, 
3d, 4c, and 4b, respectively using ampicillin as refer-
ence drug. Compound 4a showed inhibition zone of 
20.6  ±  1.5  mm in case of S. pneumoniae compared to 
inhibition zone of 23.8 ± 0.6 mm attributed to ampicillin 
while in case of B. subtilis, compound 4a showed inhibi-
tion zone of 22.1 ± 1.2 mm compared to inhibition zone 
of 26.4 ± 0.7 mm due to ampicillin. On the other hand, 
compound 4a showed the highest activity against Gram 
negative bacteria (P. aeruginosa and E. coli) compared 
Scheme 1 Synthesis of N‑(2,6‑dimethoxypyrimidin‑4‑yl)‑4‑isothiocyanato‑benzenesulfonamide 2
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Scheme 2 Synthetic route and structures for thiourea derivatives (3a–e)
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with the standard drug followed by compounds 3d, and 
4b, respectively. Compound 4a showed inhibition zone 
of 17.2 ±  1.5  mm in case of P. aeruginosa compared to 
inhibition zone of 19.7 ± 0.6 mm attributed to gentamy-
cin while in case of E. coli, compound 4a showed inhibi-
tion zone of 21.3 ± 0.8 mm compared to inhibition zone 
of 24.9 ± 1.5 mm due to gentamycin. Interestingly, com-
pounds 4c and 4d exhibited selective antibacterial activi-
ties against Gram positive bacteria.
Regarding the activity of the tested compounds against 
the tested filamentous fungus A. fumigatus, the order of 
activity 4a, 3d, and 4b. No antimicrobial activities were 
detected for compounds 3a, 3c and 3e. Also, none of the 
tested compound exerts any activity against the patho-
genic yeast species (C. albicans) under these screen-
ing conditions. Compound 4a was the most active 
compound in this case also. Compound 4a showed inhi-
bition zone of 20.1 ± 1.3 mm compared to 23.7 ± 1.2 mm 
exhibited by amphotrecin B. The antimicrobial activities 
of the most active synthesized fluorinated compounds 
were also tested to determine the minimum inhibitory 
concentration (Table 2). Moreover, compound 4a showed 
the highest activity (MIC values ranged from 1.95 to 
15.63 µg/mL), followed by 3d (MIC 7.81–250 µg/mL) and 
4b (MIC 7.81–250 µg/mL).
Structure activity relationship
Regarding activity against Gram positive bacteria, mono 
substituted fluorophenyl derivatives 3a–3c showed no 
activity also the nitro fuolorinated derivative 3e was 
also inactive. The best activity was attributed to tetra-
fluoro pyridine derivative 4a indicating that increasing 
the number of fluoro substitutions has good impact on 
activity followed by trifluoromethyl derivatives 4c and 4d 
with tri fluoro substitution and finally the fluoro methoxy 
derivative 3d and the fluorinated benzothiazole deriva-
tive 4b. Similarly, The tetrafluoro pyridine derivative 4a 
was the most active compound on Gram negative bacte-
ria. Also in case of antifungal activity the tetrafluoro pyri-
dine derivative 4a was the most active compound.
Cytotoxic activity
The in  vitro growth inhibitory activity of the synthe-
sized compounds was investigated in comparison with 
the well-known anticancer standard drugs (5-flouroura-
cil and cisplatin) under the same conditions using col-
orimetric MTT assay. Data generated were used to plot 
a dose response curve of which the concentration of 
test compounds required to kill 50% of cell population 
 (IC50) was determined (Fig. 3). The results revealed that 
all the tested compounds showed inhibitory activity to 
Fig. 2 The proposed mechanism for the formation of thiourea
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the tumor cell lines in a concentration dependent man-
ner. Cytotoxic activity was expressed as the mean  IC50 of 
three independent experiments.
Interestingly, the results are represented in Table  3 and 
Fig. 3 showed that compound 4a was the most active against 
the liver carcinoma cell line (HepG2), showing more activ-
ity than the reference drugs with  IC50 value of 4.8  μg/mL 
compared to 5-flourouracil with  IC50 value of 4.9  μg/mL 
and cisplatin with  IC50 value of 18.8  μg/mL. Compound 
3c exhibited good antitumor activity against the liver car-
cinoma cell line (HepG2) showing almost the same activity 
as cisplatin followed by 4b, 4c, 3d and 3a, respectively. The 
tested compounds showed lower tendency to inhibit the 
breast carcinoma cells than those observed for liver carci-
noma (Fig. 4). The order of activity against breast carcinoma 
cell line (MCF-7) was 4a, 3c, 4b, and 4c, respectively. More-
over, compounds 3a, 3d, 3e and 4d were less active among 
their analogues against the two tumor cell lines.
Molecular docking
One of the most important enzymes that controls signal 
transduction and cell proliferation is mitogen-activated 
Scheme 3 Synthetic route and structures for thiourea derivatives (4a–d)
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protein kinase-activated protein kinase 2 (MAPKAPK-2 
or MK-2) [39]. Discovering new inhibitors for this key 
enzyme has received attention as a strategy in the seek for 
novel anticancer agents [40]. Among the newly discov-
ered inhibitors for this enzyme, several urea and thiourea 
derivatives have showed good activity [41]. In the present 
research, several thiourea derivatives were synthesized 
and evaluated for their cytotoxic activity. The most active 
derivatives 3c and 4a–4c were docked on the active 
site of MK-2 enzyme in a trial to suggest a mechanism 
Table 1 In vitro antimicrobial activities of  the synthesized fluorinated compounds tested at  1  mg/mL by  well diffusion 
agar assay and expressed as inhibition zone diameter (mm) in the form of mean ± SD
Tested microorganisms 
compound code













3a 0 0 0 0 0 0
3b 0 0 0 0 0 0
3c 0 0 0 0 0 0
3d 16.9 ± 1.2 0 15.4 ± 0.8 18.2 ± 0.6 12.4 ± 0.8 15.1 ± 1.2
3e 0 0 0 0 0 0
4a 20.1 ± 1.3 0 20.6 ± 1.5 22.1 ± 1.2 17.2 ± 1.5 21.3 ± 0.8
4b 16.3 ± 0.5 0 14.2 ± 0.4 17.1 ± 0.6 11.2 ± 0.7 13.4 ± 0.7
4c 0 0 15.1 ± 0.7 19.8 ± 1.1 0 0
4d 0 0 16.3 ± 1.2 18.3 ± 0. 8 0 0
Amphotricin B 23.7 ± 1.2 25.4 ± 1.1
Ampicillin 23.8 ± 0.6 26.4 ± 0.7
Gentamycin 19.7 ± 0.6 24.9 ± 1.5
Table 2 The antimicrobial activities of the most active synthesized fluorinated compounds expressed as minimum inhibi-
tory concentration (µg/mL)










3d 15.63 62.5 7.81 250 62.5
4a 3.9 3.9 1.95 15.63 3.9
4b 62.5 125 15.63 250 125
Amphotricin B 1.95 – – – –
Ampicillin – 0.98 0.49 – –
Gentamycin – – – 3.9 0.98
Fig. 3 The dose response curve showing the in vitro inhibitory activity of the tested compounds against liver carcinoma (HepG2) cell line com‑
pared with reference drugs cisplatin and 5‑flourouracil
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of action for their cytotoxic activity. The protein data 
bank file (PDB: 3WI6). The file contains MK-2 enzyme 
co-crystalized with an inhibitor. All docking procedures 
were achieved by MOE (Molecular Operating Environ-
ment) software 10.2008 provided by chemical computing 
group, Canada. The inhibitor interacts with MK-2 active 
site with four hydrogen bonds involving Glu 190, Leu 
141, Asn 191 ans Asp 207 (Fig. 5). The docking protocol 
was validated by redocking of the ligand on the active site 
of MK-2 enzyme with energy score (S) = −15.4978 kcal/
mol and root mean square deviation (RMSD) = 1.1457.
The previous docking protocol was followed for com-
pounds 3c and 4a–4c. All the docked compounds were 
fit on the active site of MK-2 enzyme. Docking scores and 
amino acid interactions for the docked compounds were 
summarized in Table 4.
On a closer look on Table 4 we can conclude that: all 
four compounds showed docking score better than 
the co-crystallized ligand in the range of (−16.2293 to 
22.9000 kcal/mol). The best docking score was displayed 
by compound 4c (Fig. 6).
In case of amino acid interactions, compound 4a is the 
only compound that exhibited two interactions with Leu 
141 and Asp 207 by two hydrogen bond of 2.96 and 2.22 
Å, respectively (Fig. 7) which may explain its promising 
cytotoxic activity.
Conclusion
In conclusion, synthesis, structural elucidation, anti-
microbial and anticancer activities of a new series of 
N-(2,6-dimethoxypyrimidin-4-yl)-4-(3-(aryl) thioureido)
benzenesulfonamides 3a–e and 4a–d were reported. 
Compound 4a was the most active compound against 
Gram positive bacteria (B. subtilis and S. pneumoniae), 
Gram negative bacteria (P. aeruginosa and E. coli) and 
fungi (A. fumigatus). Interestingly, compounds 4c and 4d 
were selective to Gram positive bacteria. Compound 4a 
was the most active compound in cytotoxic assay against 
breast cancer cell line (MCF-7) and hepatic cancer cell 
line (HepG2). Compound 4a was more active than the 
standard drug 5-flourouracil in case of hepatic cancer cell 
line (HepG2). Molecular docking of compound 4a on the 
active site of mitogen activated kinase (MK-2) revealed 
good amino acid interactions.
Experimental
General chemistry
Melting points (uncorrected) were determined in an 
open capillary in a Gallenkamp melting point apparatus 
(Sanyo Gallenkamp, UK). Pre coated silica gel plates (Kie-
selgel 0.25 mm, 60 F254, Merck, Germany) were used for 
thin layer chromatography. A developing solvent system 
of chloroform/methanol (8:2) was used and the spots 
were detected by ultraviolet light. IR spectra (KBr disc) 
were recorded using an FT-IR spectrophotometer (Per-
kin Elmer, USA). 1H NMR spectra were scanned on an 
NMR spectrophotometer (Bruker AXS Inc., Switzerland), 
Table 3 The antitumor activities of the tested compounds 
expressed as   IC50 values and  compared with  reference 
standard drugs evaluated on  breast and  liver cancer cell 
lines
Tested compounds IC50 values (µg/mL) against tumor 
cell lines
MCF-7 HepG2
3a >200 153.1 ± 2.3
3b NA NA
3c 41.9 ± 1.7 18.8 ± 1.1
3d >200 150.9 ± 3.7
3e >200 >200
4a 22.3 ± 1.5 4.8 ± 0.6
4b 46.1 ± 1.6 24.5 ± 1.2
4c 63.8 ± 1.2 45.2 ± 1.4
4d >200 >200
5‑flourouracil 5.2 ± 0.5 4.9 ± 0.3
Cisplatin 19.1 ± 0.7 18.8 ± 0.6
Fig. 4 The dose response curve showing the in vitro inhibitory activity of the tested compounds against breast carcinoma (MCF‑7) cell line com‑
pared with reference drugs cisplatin and 5‑flourouracil
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operating at 500  MHz for 1H- and 125.76  MHz for 13C 
NMR. Chemical shifts are expressed in δ values (ppm) 
relative to TMS as an internal standard, using DMSO-d6 
as a solvent. Elemental analyses were done on a model 
2400 CHNSO analyser (Perkin Elmer, USA). All values 
were within ±0.4% of the theoretical values. All reagents 
used were of AR grade.
Fig. 5 Co‑crystallized ligand in the active site of mitogen activated kinase (MK‑2)
Table 4 Docking scores and  amino acid interactions of  the docked compounds on  the active site of  mitogen activated 
kinase (MK-2)
Compounds (S) Kcal/mol Amino acid Interacting group Type of interaction H-bond length (Å)
3c −18.8805 Asp 207 NH H bond (donor) 1.25








4b −16.2293 Asp 207 NH H bond (donor) 2.12
4c −22.9000 Asp 207 NH H bond (donor) 1.53
General procedure for N-(2,6-dimethoxypyrimi-
din-4-yl)-4-(3- (aryl) thioureido)benzenesulfonamides 3a–e 
and 4a–d
To a mixture of isothiocyanatobenzenesulfonamide 2 
(0.01 mol) and fluorinated aromatic amine (0.01 mol) in 
dioxane (30 mL), triethylamine (0.1 mL) was added. The 
reaction mixture was heated under reflux for 1  h. The 
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Fig. 6 Compound 4c in the active site of mitogen activated kinase (MK‑2)
Fig. 7 Compound 4c in the active site of mitogen activated kinase (MK‑2)
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solvent was removed by evaporation under reduced pres-
sure and the remainder was left to cool. The solid prod-
uct so formed was collected by filtration, washed with 
petroleum ether (bp 40–60  °C) and the crude product 
recrystallized from ethanol to afford thiourea derivatives.
N‑(2, 6‑Dimethoxy‑pyrimidin‑4‑yl)‑4‑[3‑(2‑fluoro‑phenyl)
‑thioureido]enzene‑sulfonamide (3a)
This compound was obtained as brown crystals from etha-
nol; yield 83%; m.p. 348.1 °C. IR: 3444, 3354, 3232 (NH), 3091 
(arom.), 2956, 2810 (aliph.), 1568 (CN), 1361, 1180  (SO2), 
1265 (CS). 1HNMR: δ 3.81, 3.84 [2 s, 6H,  2OCH3], 5.9 [s, 1H, 
H- pyrimidine], 6.7–8.0 [m, 8H, Ar–H], 10.2 [s, 1H,  SO2NH], 
11.8, 14.0 [2 s, 2H, 2NH]; 13C-NMR: 55.2, 55.8, 87.0, 113.1, 
122.9 (3), 128.4 (2), 129.1 (2), 131.5, 133.8, 140.0, 162.7 (2), 
165.3, 170.2, 182.0. Anal. Calcd. for  C19H18FN5O4S2:C, 
49.24%; H, 3.91%; F, 4.10%; N, 15.11%; S, 13.84%. Found: C, 
49.30%; H, 3.80%; F, 4.20%; N, 15.12%; S, 13.84%.
N‑(2,6‑Dimethoxy‑pyrimidin‑4‑yl)‑4‑[3‑(3‑fluoro‑phenyl)‑thi‑
oureido]benzene‑sulfonamide (3b)
This compound was obtained as brown crystals from eth-
anol; yield 87%; m.p. 133.9 °C. IR: 3446, 3365 (NH), 3100 
(arom.), 2978, 2831 (aliph.), 1635 (CN), 1396, 1182  (SO2), 
1274 (CS). 1HNMR: δ 3.80, 3.83 [2 s, 6H,  2OCH3], 6.4 [s, 
1H, H -pyrimidine], 6.9–8.4 [m, 8H, Ar–H], 9.8 [s, 1H, 
 SO2NH], 11.7 [s, 2H, 2NH]; 13C-NMR: 55.4, 56.5, 80.0, 
112.7, 120.6, 121.2, 123.7 (2), 128.1 (2), 132.6 (2), 137.0, 
142.6, 163.0, 164.5, 164.9, 178.4, 179.8. Anal. Calcd. for 
 C19H18FN5O4S2:C, 49.24%; H, 3.91%; F, 4.10%; N, 15.11%; 




This compound was obtained as brown crystals from 
ethanol; yield 90%; m.p.  >  360  °C. IR: 3442, 3186 (NH), 
3062 (arom.), 2941, 2839 (aliph.), 1624 (CN), 1382, 1132 
 (SO2), 1271 (CS). 1H-NMR: δ 3.72, 3.75 [2 s, 6H,  2OCH3], 
6.4 [s, 1H, H- pyrimidine], 6.9–8.8 [m, 8H, Ar–H], 9.7 [s, 
1H,  SO2NH], 11.4 [s, 2H, 2NH]. 13C-NMR: δ 55.4, 55.7, 
84.1, 113.6 (2), 121.0 (2), 127.5 (2), 129.6 (2), 132.7, 133.8, 
140.0, 158.6, 161.9, 165.8, 170.9, 182.3. Anal. Calcd. For 
 C19H18FN5O4S2:C, 49.24%; H, 3.91%; F, 4.10%; N, 15.11%; S, 
13.84%. Found: C, 49.10%; H, 3.80%; N, 15.30%; S, 13.70%.
N‑(2,6‑Dimethoxy‑pyrimidin‑4‑yl)‑4‑[3‑(3‑fluoro‑4‑meth‑
oxy‑phenyl)‑thioureido]benzenesulfonamide (3d)
This compound was obtained as yellow crystals from eth-
anol; yield 88%; m.p. 289  °C. IR: 3421, 3230 (NH), 3086 
(arom.), 2910, 2841 (aliph.), 1624 (CN), 1400, 1128  (SO2), 
1286 (CS). 1H-NMR: δ 3.84, 3.91, 3.96 [3 s, 9H,  3OCH3], 
6.4 [s, 1H, H-pyrimidine], 6.9–8.4 [m, 7H, Ar–H], 8.9 [s, 
1H,  SO2NH], 11.5 [s, 2H, 2NH];13C-NMR:δ 55.4, 55.6, 
57.4, 79.6, 117.3 (2), 121.7 (2), 122.0, 129.7(2), 130.1, 
134.7, 139.8, 140.9, 150.8, 160.2, 162.9, 172.0, −183.3. 
Anal. Calcd. For  C20H20FN5O5S2:C, 48.67%; H, 4.08%; F, 
3.85%; N, 14.19%; O, 16.21%; S, 12.99%. Found: C, 48.50%; 
H, 4.10%; F, 3.30%; N, 14.20%; S, 12.70%.
N‑(2,6‑Dimethoxy‑pyrimidin‑4‑yl)‑4‑[3‑(4‑fluoro‑2‑ni‑
tro‑phenyl)‑thioureido]benzenesulfonamide (3e)
This compound was obtained as yellow crystals from 
ethanol; yield 86%; m.p. 143.5  °C. IR: 3421, 3197 (NH), 
3062 (arom.), 2936, 2839 (aliph.), 1625 (CN), 1384, 1132 
 (SO2), 1269 (CS). 1H-NMR: δ3.80, 3.84 [2 s, 6H,  2OCH3], 
6.5 [s, 1H, H-pyrimidine], 6.9–8.4 [m, 7H, Ar–H], 9.8 
[s, 1H,  SO2NH], 10.4, 11.0 [2  s, 2H, 2NH]. 13C-NMR: 
55.4, 56.5, 79.8, 112.7, 121.4, 125.5 (2), 127.8 (2), 128.1 
(2), 133.6, 144.0, 144.9, 153.1, 155.3, 165.7, 170.2, 178.8. 
Anal. Calcd. For  C19H19FN6O6S2: C, 44.70%; H, 3.75%; F, 
3.72%; N, 16.46%; S, 12.56%. Found: C, 44.60%; H, 3.50%; 
F, 3.70%; N, 16.40%; S, 12. 60%.
N‑(2,6‑Dimethoxy‑pyrimidin‑4‑yl)‑4‑[3‑(2,3,5,6‑tetra‑
fluoro‑pyridin‑4‑yl)‑thioureido]benzenesulfonamide (4a)
This compound was obtained as brown crystals from 
ethanol; yield 87%; m.p. 281.7  °C.IR: 3400, 3192 (NH), 
3057 (arom.), 2931, 2871 (aliph.), 1620 (CN), 1386, 1128 
 (SO2), 1257 (CS). 1H-NMR:δ 3.80, 3.84 [2 s, 6H,  2OCH3], 
6.1 [s, 1H, H-pyrimidine], 6.7–8.2 [m, 4H, Ar–H],10.3 
[s, 1H,  SO2NH], 11.7 [s, 2H, 2NH]; 13C-NMR: δ 55.4, 
55.6, 81.2, 121.8 (2),128.7 (2), 130.2(2), 137.1, 140.8, 
143.0, 144.5 (2), 161.4, 161.9, 169.7, 184.6. Anal. Calcd. 
For  C18H14F4N6O4S2:C, 41.60%; H, 2.42%; F, 14.60%; N, 
16.30%; S, 12.40%. Found: C, 41.60%; H, 2.42%; F, 14.60%; 
N, 16.30%; S, 12.40%.
N‑(2,6‑Dimethoxy‑pyrimidin‑4‑yl)‑4‑[3‑(5‑trifluoromethyl‑[1, 
3, 4]thiadiazol‑2‑yl)‑thioureido]‑benzenesulfonamide (4b)
This compound was obtained as brown crystals from 
ethanol; yield 86%; m.p. 276.7  °C. IR: 3400, 3201(NH), 
3045 (arom.), 2923, 2801 (aliph.), 1622 (CN),1386,1130 
 (SO2),1323 (CS). 1H-NMR: δ 3.80, 3.81 [2 s, 6H,  2OCH3], 
6.1 [s, 1H, H-pyrimidine],6.9–8.4 [m, 4H, Ar–H], 10.1 
[s, 1H,  SO2NH], 10.3, 12.0 [2  s,2H, 2NH]; 13C-NMR: 
56.2, 56.7, 81.6, 117.2, 120.8 (2), 130.7 (2), 134.6, 143.0, 
151.1, 154.6, 161.7, 163.9, 173.0, 182.8. Anal. Calcd. 
for  C16H14F3N7O4S3:C, 36.85%; H, 2.71%; F, 10.93%; N, 
18.80%; S, 18.45%. Found: C, 36.70%; H, 2.90%; F, 10.70%; 
N, 18.90%; S, 18.90%.
N‑(2,6‑Dimethoxy‑pyrimidin‑4‑yl)‑4‑[3‑(6‑fluoro‑benzothi‑
azol‑2‑yl)‑thioureido]‑benzenesulfonamide (4c)
This compound was obtained as brown crystals from 
ethanol; yield 92%; m.p.179.7  °C. IR: 3415, 3310 (NH), 
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3075 (arom.), 2978, 2841 (aliph.), 618 (CN), 1311, 
1195  (SO2),1274 (CS).1H-NMR: δ 3.64, 3.66 [2  s, 6H, 
 2OCH3], 6.5 [s, 1H, H-pyrimidine], 6.9–8.5 [m, 7H, Ar–
H],9.7[s,1H,  SO2NH],11.8, 12.4 [2 s, 2H, 2NH].13C-NMR: 
55.4, 55.8, 83.7, 109.1, 112.0, 119.2, 123.7 (2), 128.1 (2), 
132.8, 134.2, 139.9, 147.1, 156.6, 157.1, 165.3, 174.0, 
175.1, 183.2. Anal. Calcd. for  C20H17FN6O4S3: C, 46.14%; 
H, 3.29%; F, 3.65%; N, 16.14%; S, 18.48%. Found: C, 




This compound was obtained as brown crystals from 
ethanol; yield 81%; m.p.209.7  °C. IR: 3454, 3361, 3250 
(NH), 3100 (arom.), 2970, 2861 (aliph.), 1708 (CO), 1635 
(CN),1350,1165  (SO2), 1286 (CS). 1H-NMR: 3.80, 3.82 
[2  s, 6H,  2OCH3], 6.3 [s, 1H, H -pyrimidine], 6.8–8.0 
[m, 8H, Ar–H  +  H -chromene], 9.8 [s, 1H,  SO2NH], 
11.4 [s,2H, 2NH]; 13C-NMR: 55.4, 55.6, 80.6, 107.2, 
112.6 (2), 121.3 (2), 126.1 (3), 129.0 (2), 133.0 (2), 140.5, 
154.5 (2), 157.0, 159.8, 165.2, 174.6, 180.3. Anal. Calcd. 
for  C23H18F3N5O6S2: C, 47.50%; H, 3.12%; F, 9.80%; N, 
12.04%; S, 11.03%. Found:C, 47.70%; H, 3.50%; F, 9.70%; 
N, 12.30%; S, 11.20%.
Antimicrobial activity assay
All microbial strains were provided from culture collec-
tion of the Regional Center for Mycology and Biotech-
nology (RCMB), Al-Azhar University, Cairo, Egypt. The 
antimicrobial activity was investigated on a dozen of 
newly synthesized compounds in order to increase the 
selectivity of these derivatives towards test microorgan-
isms using well diffusion method [42]. Briefly, 100  μL 
of the test bacteria/fungi were grown in 10 mL of fresh 
media until they reached a count of approximately  108 
cells/mL for bacteria or  105 cells/mL for fungi. One 
hundred µL of each sample (at 1  mg/mL) was added to 
each well (10  mm diameter holes cut in the agar gel). 
The plates were incubated for 24–48 h at 37 °C (for bac-
teria and yeast) and for 48  h at 28  °C (for filamentous 
fungi). After incubation, the microorganism’s growth 
was observed. Ampicillin and gentamycin were used as 
standard antibacterial drugs while amphotricin B was 
used as standard antifungal drug. The resulting inhibition 
zone diameters were measured in millimeters and used 
as criterion for the antimicrobial activity. If an organism 
is placed on the agar it will not grow in the area around 
the well if it is susceptible to the chemical. This area of no 
growth around the disc is known as a zone of inhibition. 
The size of the clear zone is proportional to the inhibi-
tory action of the compound under investigation. Solvent 
controls (DMSO) were included in every experiment as 
negative controls. DMSO was used for dissolving the 
tested compounds and showed no inhibition zones, con-
firming that it has no influence on growth of the tested 
microorganisms. The active compounds were further 
investigated to determine their antimicrobial activity 
expressed in terms of minimum inhibitory concentra-
tion (MIC) using the modified agar well diffusion method 
that mentioned above. Concentrations between 0.1 and 
1000  µg/mL of each active compound were tested and 
compared with standard drugs. The MIC was then deter-
mined as the lowest concentration inhibiting growth of 
the organism after 24–48 h.
Antitumor activity assay
The tested human carcinoma cell lines were obtained 
from the American Type Culture Collection (ATCC, 
Rockville, MD). The cells were grown on RPMI-1640 
medium supplemented with 10% inactivated fetal calf 
serum and 50  µg/mL gentamycin. The cells were main-
tained at 37 °C in a humidified atmosphere with 5%  CO2 
and were sub-cultured two to three times a week.
For antitumor assays, the tumor cell lines were sus-
pended in medium at cell density of 5 × 104 cells/well in 
 Corning® 96-well tissue culture plates, then incubated 
for 24  h. The tested compounds were then added into 
96-well plates (six replicates) to achieve eight concentra-
tions for each compound. Six vehicle controls with media 
or 0.5% DMSO were run for each 96 well plate as a con-
trol. After incubating for 24 h, the numbers of viable cells 
were determined by the MTT assay [43, 44]. Briefly, the 
media was removed from the 96-well plate and replaced 
with 100 µL of fresh culture RPMI 1640 medium without 
phenol red then 10  µL of the 12  mM MTT stock solu-
tion (5 mg of MTT in 1 mL of PBS) to each well includ-
ing the untreated controls. The 96 well plates were then 
incubated at 37 °C and 5%  CO2 for 4 h. An 85 µL aliquot 
of the media was removed from the wells, and 50 µL of 
DMSO was added to each well and mixed thoroughly 
with the pipette and incubated at 37 °C for 10 min. Then, 
the optical density was measured at 590  nm with the 
microplate reader (SunRise, TECAN, Inc, USA) to deter-
mine the number of viable cells and the percentage of 
viability was calculated as [1−(ODt/ODc)] × 100% where 
ODt is the mean optical density of wells treated with the 
tested sample and ODc is the mean optical density of 
untreated cells. The relation between surviving cells and 
drug concentration is plotted to get the survival curve 
of each tumor cell line after treatment with the specified 
compound. The 50% inhibitory concentration  (IC50), the 
concentration required to cause toxic effects in 50% of 
intact cells, was estimated from graphic plots of the dose 
response curve for each conc. using Graphpad Prism 
software (San Diego, CA, USA) [31].
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Molecular docking
All the molecular modeling studies were carried out on 
an Intel Pentium 1.6  GHz processor, 512  MB memory 
with Windows XP operating system using Molecular 
Operating Environment (MOE, 10.2008) software. All the 
minimizations were performed with MOE until a RMSD 
gradient of 0.05  kcal  mol−1  Å−1 with MMFF94X force 
field and the partial charges were automatically calcu-
lated. The protein data bank file (PDB:3WI6) was selected 
for this purpose. The file contains MK-2 enzyme Co-crys-
talized with a ligand obtained from protein data bank. 
The enzyme was prepared for docking studies where: (i) 
Ligand molecule was removed from the enzyme active 
site. (ii) Hydrogen atoms were added to the structure with 
their standard geometry. (iii) MOE Alpha Site Finder was 
used for the active sites search in the enzyme structure 
and dummy atoms were created from the obtained alpha 
spheres. (iv) The obtained model was then used in pre-
dicting the ligand enzymes interactions at the active site.
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